Product Images Acam2000
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Acam2000 NDC 71665-330 by Emergent Product Development Gaithersburg Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
ACAM Vial Label.jpg - ACAM Vial Label
This is a description of a smallpox vaccine named ACAM2000® . It is only for use in the Strategic National Stockpile and should be stored between 2-8°C (36-46°F). The vaccine must be used within thirty days of reconstitution and should only be administered percutaneously with a bifurcated needle. It should not be given intravenously. The vaccine has a fill volume of 0.3 mL/100 doses and a potency of 1-5x10^8 PFU/mL. The manufacturer of this vaccine is Emergent Product Development in Gaithersburg, MD 20879 USA.*
M:\RA\ectd\SPL\Labels\ACAM\April 2018\MedGuide Image 1 expected response.jpg - image 01
MedGuide Image 1 infected arm.jpg - image 02
MedGuide Image 2 Infected eye.jpg - image 03
ACAM Carton Label.jpg - image 04
This is a description of the Smallpox (Vaccinia) Vaccine, Live called ACAM2000. It is administered through percutaneous inoculation with Bifurcated Needle only and contains trace amounts of antibiotics (Neomycin and Polymyxin B). The vaccine has an approximate dose of 2.5 uL and a potency of 1-5x108 PFU/mL. The expiration date is indicated, and the vaccine should be stored at -25 to -15°C (-13 to 5°F) until distributed for use. After distribution, it may be stored at 2-8°C (36-46°F) for up to 18 months and should be used within 30 days of reconstitution. The manufacturer is Emergent Product Development Gaithersburg Inc. The package insert should be referred to for full prescribing and product information.*
Images of the expected cutaneous reaction from Day 3 to Day 14 after revaccination showing modified (reduced) reaction compared to primary vaccination. - rad643FE.tmp 00
Images of the expected cutaneous reaction after primary vaccination showing progression from a vesicle (Day 5) to a pustule (Days 8-10) to a scab (Day 14). - rad643FE.tmp 01
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.